Physician profile
Sayfe Ali Jassim
NPI 1508206111
$459,724.97
in general payments reported to CMS, 2019-2025
13 companies · $131K in 2025
The $131K reported for 2025 was more than what 97% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,414 · 2020: $6,011 · 2021: $65K · 2022: $127K · 2023: $66K · 2024: $55K · 2025: $131K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $228K · Travel and Lodging: $20K · Food and Beverage: $4,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $227,863.75 |
| Travel and Lodging | $19,575.65 |
| Food and Beverage | $4,526.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $422,248.13 | 2019-2025 | Attune, Actis, Velys |
| Depuy Synthes Products, INC. | $20,426.61 | 2023-2025 | Velys, Attune, Actis |
| Depuy Synthes Sales INC. | $9,513.56 | 2019-2025 | Velys, Attune, Actis |
| Smith+Nephew, INC. | $4,593.82 | 2019-2021 | |
| Arthrex, INC. | $1,919.61 | 2019 | |
| Conetic Solutions, INC. | $381.67 | 2019 | |
| Stryker Corporation | $176.15 | 2019-2025 | Gamma |
| Zimmer Biomet Holdings, INC. | $137.13 | 2019 | |
| Ethicon US, LLC | $112.95 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $99.64 | 2021 | |
| Innovation Technologies INC | $79.35 | 2022 | |
| Bioventus LLC | $24.05 | 2019 | |
| Bone Support INC. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayfe Jassim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.